Form 4: Edwards Lifesciences Executive Daniel J. Lippis Reports Stock Transactions

Daniel J. Lippis, CVP of JAPAC at Edwards Lifesciences, reports the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 trading plan.

Summary

• On June 20, 2024, Daniel J. Lippis, CVP of JAPAC at Edwards Lifesciences, reported transactions involving Edwards Lifesciences Corp [EW] common stock.
• Lippis exercised stock options to acquire 535 shares at a price of $45.2767 per share.
• Simultaneously, Lippis sold 535 shares at $90 per share.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2023.
• Following these transactions, Lippis directly owns 23,512.7443 shares of Edwards Lifesciences common stock and holds options for 5,030 shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't convey any particularly positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the impact is likely minimal given the relatively small number of shares involved.

Key Dates